TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9140680
Drug: Captopril 12.5-50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril 12.5-50 mg daily
Study: 8197755
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg S(+) ibuprofen daily (3 x 200mg) for 14 days
Study: 8197755
Drug: 900 mg
Normalized name: diosmin 900 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 900 mg S(+) ibuprofen daily (3 x 300mg) for 14 days
Study: 3585223
Drug: Dopamine (1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dopamine (1.0 microgram/kg per min) with angiotensin II infusion
Study: 3585223
Drug: Dopamine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dopamine infusion (graded doses: 0.5, 1 and 5 micrograms/kg per min) with angiotensin II (6 ng/kg per min)
Study: 3585223
Drug: Placebo with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo with angiotensin II infusion
Study: 1646068
Drug: Single-dose dactinomycin
Normalized name: Dactinomycin
DrugBank: Dactinomycin (DB00970)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single-dose dactinomycin (60 micrograms/kg x 1 day)
Study: 1646068
Drug: Fractionated-dose dactinomycin
Normalized name: Dactinomycin
DrugBank: Dactinomycin (DB00970)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fractionated-dose dactinomycin (15 micrograms/kg/d x 5 days)
Study: 1274885
Drug: Daily protein
Normalized name: Supra Clens Daily Protein Remover
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily protein intake of 29 g
Study: 1274885
Drug: Daily protein
Normalized name: Supra Clens Daily Protein Remover
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily protein intake of 54 g
Study: 1274885
Drug: Daily protein
Normalized name: Supra Clens Daily Protein Remover
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily protein intake of 84 g
Study: 31558274
Drug: 2-implant group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2-implant group (n=22)
Study: 31558274
Drug: Single-implant group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-implant group (n=11)
Study: 31558274
Drug: Single-implant participants
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-implant participants
Study: 31558274
Drug: 2-implant participants
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2-implant participants
Study: 10783998
Drug: Non-sulphasalazine 5-ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-sulphasalazine 5-ASA drug
Study: 8875814
Drug: Methylphenidate (MPH)
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylphenidate (MPH) 5‐mg, 10‐mg, 15‐mg, 20‐mg
Study: 6337306
Drug: Propranolol 80
Normalized name: propranolol 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol 80 mg daily postoperatively
Study: 27649641
Drug: Gonadotropin‐releasing hormone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gonadotropin‐releasing hormone agonist (GnRHa) goserelin
Study: 24091175
Drug: Prophylactic doses
Normalized name: polylactic acid-polyglycolic acid copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic doses of low molecular weight heparin
Study: 16394886
Drug: Subcutaneous bolus
Normalized name: subcutaneous bolus insulin patch pump, 200 unit, disposable 2 unit MISCELL EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous bolus injection of deferoxamine (DFO)
Study: 16394886
Drug: Subcutaneous continuous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous continuous infusion of deferoxamine (DFO)
Study: 16394886
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups (Subcutaneous bolus injection and Subcutaneous continuous infusion)
Study: 11117271
Drug: Local allergoid
Normalized name: docusate calcium / phenolphthalein Oral Capsule [Docal]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local allergoid immunotherapy for 3 months before the pollen season
Study: 9338948
Drug: Extra self‐administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extra self‐administered fitness training
Study: 3887393
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment with anti-thymocyte globulin (ATG)
Study: 3887393
Drug: Sequential combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential combination of ATG with Cys
Study: 30821824
Drug: Gabapentin (1200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gabapentin (1200 mg preoperatively, 600 mg 3 times a day postoperatively for 72 hours)
Study: 30821824
Drug: Active placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active placebo (lorazepam 0.5 mg preoperatively, inactive placebo postoperatively for 72 hours)
Study: 28159043
Drug: Prophylactic antibiotics
Normalized name: polylactic acid-polyglycolic acid copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic antibiotics (Group 1)
Study: 28159043
Drug: No prophylactic
Approvals — FDA: no, EMA: no, PMDA: no
Description: No prophylactic antibiotics (Group 2)
Study: 12635534
Drug: Azithromycin alone
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Azithromycin alone (500 mg i.v. for 1-2 days, then 250 mg orally for 7 days)
Study: 12635534
Drug: Azithromycin with
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Azithromycin with metronidazole (500 mg i.v. for 1-2 days, then 250 mg orally for 7 days + 400 mg or 500 mg metronidazole i.v. then orally for 12-14 days)
Study: 12635534
Drug: All treatment
Normalized name: UNDECYLENIC ACID 8 g in 30 mL / TOLNAFTATE 1 g in 30 mL TOPICAL LIQUID [Fugal nall treatment]
Approvals — FDA: no, EMA: no, PMDA: no
Description: All treatment groups (including azithromycin alone, azithromycin with metronidazole, and comparator regimens)
Study: 10874261
Drug: Enalaprilat infusion
Normalized name: Enalaprilat
DrugBank: Enalaprilat (DB09477)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Enalaprilat infusion (3-hour duration)
Study: 8517425
Drug: Pravastatin (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pravastatin (40 mg) administered once daily at bedtime
Study: 8517425
Drug: Placebo administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered once daily at bedtime
Study: 23653431
Drug: Vitamin D-
Normalized name: Vitamin D-3
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D- and calcium-fortified yogurt (FY) providing 10 μg/d vitamin D₃ and 800 mg/d calcium
Study: 23653431
Drug: Nonfortified control
Normalized name: thiamine
DrugBank: Thiamine (DB00152)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nonfortified control yogurt (CY) providing 280 mg/d calcium
Study: 10799795
Drug: Diclofenac epolamine
Normalized name: Diclofenac Epolamine
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Diclofenac epolamine patch applied twice daily for 2 weeks
Study: 10799795
Drug: Placebo patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo patch applied twice daily for 2 weeks
Study: 23224717
Drug: Selective reporting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selective reporting of antibiotic susceptibility data (2 to 4 antibiotics only)
Study: 23224717
Drug: Usual full-length
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual full-length reporting of antibiotic susceptibility data (25 antibiotics)
Study: 23224717
Drug: Selective reporting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selective reporting of antibiotic susceptibility data
Study: 23224717
Drug: Usual full-length
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual full-length reporting of antibiotic susceptibility data
Study: 25085407
Drug: Chlorhexidine solution
Normalized name: CHLORHEXIDINE GLUCONATE 99.0 g in 1 L TOPICAL SOLUTION [CHLORHEXIDINE Solution]
DrugBank: Chlorhexidine (DB00878)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chlorhexidine solution
Study: 11118018
Drug: Continuous subcutaneous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous subcutaneous infusion of insulin lispro (CSII)
Study: 11118018
Drug: Ultralente human
Normalized name: INSULIN,ULTRALENTE,HUMAN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultralente human insulin
Study: 11118018
Drug: Long-acting insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long-acting insulin analog glargine
Study: 9007918
Drug: Topical fluocinolone
Normalized name: fluocinolone Topical Ointment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical fluocinolone acetonide 0.1%
Study: 9007918
Drug: Topical retinoic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical retinoic acid 0.05%
Study: 8117604
Drug: Induction chemotherapy
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction chemotherapy (cisplatin 100 mg/m2 on day 1 and etoposide 120 mg/m2 on days 1, 2, 3 every 3 weeks for 3 courses followed by radiotherapy 56 Gy on pre-treatment tumor volume and 40 Gy on mediastinum and bilateral supraclavicular nodes)
Study: 3086849
Drug: Patch A
Normalized name: Biopatch Antimicrobial Dressing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patch A
Study: 3086849
Drug: Patch B
Normalized name: Eye Patch Black
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patch B
Study: 3086849
Drug: Patch C
Normalized name: WellPatch CAPSAICIN 0.025 % Medicated Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patch C
Study: 3086849
Drug: Comparison between
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison between patches A and B
Study: 27102981
Drug: Sublingual misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sublingual misoprostol 800μg
Study: 27102981
Drug: Buccal misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Buccal misoprostol 800μg
Study: 27102981
Drug: Oral misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral misoprostol 800μg
Study: 25069975
Drug: mRDTs introduced
Normalized name: PERCUTANEOUS INTRODUCER SET
Approvals — FDA: no, EMA: no, PMDA: no
Description: mRDTs introduced in drug shops
Study: 20429831
Drug: EC-ASA 81
Approvals — FDA: no, EMA: no, PMDA: no
Description: EC-ASA 81 mg once daily alone
Study: 20429831
Drug: EC-ASA 81
Approvals — FDA: no, EMA: no, PMDA: no
Description: EC-ASA 81 mg once daily with acetaminophen 1 g four times daily
Study: 20429831
Drug: EC-ASA 81
Approvals — FDA: no, EMA: no, PMDA: no
Description: EC-ASA 81 mg once daily with NAPSO 220 mg three times daily
Study: 15939585
Drug: Third-generation non-steroidal
Normalized name: Third-generation cephalosporins
Approvals — FDA: no, EMA: no, PMDA: no
Description: Third-generation non-steroidal aromatase inhibitors (NS-AIs) anastrozole and letrozole
Study: 15939585
Drug: Steroidal aromatase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroidal aromatase inhibitor (S-AI) exemestane
Study: 12442882
Drug: Donepezil 5
Normalized name: donepezil 5 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Donepezil 5 mg/day for the first 28 days and 10 mg/day thereafter (n = 102)
Study: 10442786
Drug: Various treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Various treatments in psychiatry
Study: 10442786
Drug: Proven treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proven treatments applied by psychiatrists
Study: 1632690
Drug: Preoperative radiation
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative radiation therapy and surgery (subset of 56 patients with locally advanced lesions)
Study: 30914312
Drug: 19-G EBUS
Normalized name: MENTHOL 19 g in 100 TOPICAL PATCH
Approvals — FDA: no, EMA: no, PMDA: no
Description: 19-G EBUS needle
Study: 30914312
Drug: 22-G EBUS
Normalized name: zinc oxide
DrugBank: Zinc oxide (DB09321)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 22-G EBUS needle
Study: 27837934
Drug: Selumetinib 75
Normalized name: Sélumétinib
DrugBank: Selumetinib (DB11689)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Selumetinib 75 mg
Study: 27837934
Drug: Selumetinib 150
Normalized name: Sélumétinib
DrugBank: Selumetinib (DB11689)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Selumetinib 150 mg (predicted)
Study: 24840317
Drug: INSULIN‐PH20
Approvals — FDA: no, EMA: no, PMDA: no
Description: INSULIN‐PH20
Study: 18320064
Drug: CPG-DDS +
Normalized name: DDS
DrugBank: Dapsone (DB00250)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CPG-DDS + artesunate 1 mg/kg
Study: 18320064
Drug: CPG-DDS +
Normalized name: DDS
DrugBank: Dapsone (DB00250)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CPG-DDS + artesunate 2 mg/kg
Study: 18320064
Drug: CPG-DDS +
Normalized name: DDS
DrugBank: Dapsone (DB00250)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CPG-DDS + artesunate 4 mg/kg
Study: 18320064
Drug: Treatment emergent
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment emergent adverse events
Study: 10874989
Drug: Maternal prepartum
Normalized name: undecylenate
DrugBank: Undecylenic acid (DB11117)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Maternal prepartum treatment with antibiotics and/or steroids
Study: 8609325
Drug: Ibutilide (0.005
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibutilide (0.005 to 0.025 mg/kg body weight)
Study: 7295460
Drug: Phenobarbitone 80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenobarbitone 80 mg
Study: 7295460
Drug: Phenobarbitone 140
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenobarbitone 140 mg
Study: 7295460
Drug: Phenobarbitone 240
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenobarbitone 240 mg
Study: 7295460
Drug: Phenobarbitone (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenobarbitone (all doses)
Study: 24842062
Drug: Initial bone
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Initial bone preparation followed by a 2-week delay before implant placement
Study: 21400763
Drug: Surgical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical treatment for cruciate ligament injury
Study: 12487321
Drug: Camphor-Crataegus berry
Approvals — FDA: no, EMA: no, PMDA: no
Description: Camphor-Crataegus berry combination (CCC) - 5 drops
Study: 12487321
Drug: Camphor-Crataegus berry
Approvals — FDA: no, EMA: no, PMDA: no
Description: Camphor-Crataegus berry combination (CCC) - 20 drops
Study: 12487321
Drug: Camphor-Crataegus berry
Approvals — FDA: no, EMA: no, PMDA: no
Description: Camphor-Crataegus berry combination (CCC) - 80 drops
Study: 12487321
Drug: Placebo (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (20 drops of a 60% alcoholic solution)
Study: 2658793
Drug: Single-beta-lactam combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-beta-lactam combination
Study: 31895303
Drug: Kangaroo mother
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kangaroo mother care (n = 30), provided twice a day until discharge
Study: 29050753
Drug: Spray Cryotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spray Cryotherapy (SCT)
Study: 26086183
Drug: NBP 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: NBP 200 mg three times daily
Study: 1637215
Drug: Glucose-insulin-potassium infusion
Normalized name: glucose / potassium chloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucose-insulin-potassium infusion (500 mL of 30% glucose containing 300 units of insulin and 5 g of potassium chloride at a rate of 1.66 mL.kg‐1.h‐1 for 1 hour before cardiopulmonary bypass)
Study: 27233840
Drug: Nicotine Replacement
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicotine Replacement Therapy (NRT) - 21 mg daily maximum for 10 weeks
Study: 27233840
Drug: Nicotine Replacement
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicotine Replacement Therapy Plus (NRT+) - 35 mg daily maximum patches and gum/inhaler for up to 22 weeks
Study: 27233840
Drug: Varenicline (VR)
Normalized name: Prostin VR
DrugBank: Varenicline (DB01273)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Varenicline (VR) - 1 mg twice daily for up to 24 weeks
Study: 24590752
Drug: Prenatal lipid‐based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prenatal lipid‐based nutrient supplements (LNS)
Study: 21785956
Drug: Multidisciplinary treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multidisciplinary treatment program including massage therapy, ischemic pressure, aerobic exercise, and thermal therapy for 8 weeks
Study: 21785956
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group continued medical treatment and participated in four educational sessions
Study: 22258622
Drug: Classification-based treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Classification-based treatment
Study: 17346248
Drug: Oxcarbazepine (OXCZ)
Normalized name: Oxcarbazepine
DrugBank: Oxcarbazepine (DB00776)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oxcarbazepine (OXCZ) 1200 mg daily for 17 days
Study: 17346248
Drug: Carbamazepine (CBZ)
Normalized name: Carbamazepine
DrugBank: Carbamazepine (DB00564)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Carbamazepine (CBZ) 800 mg daily for 17 days
Study: 30997657
Drug: Cavit G
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cavit G
Study: 21389120
Drug: MHD intravenously
Approvals — FDA: no, EMA: no, PMDA: no
Description: MHD intravenously (250 mg infused over 30 min)
Study: 21389120
Drug: OXC orally
Normalized name: oxcarbazepine Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: OXC orally (one film-coated 300-mg tablet)
Study: 11920979
Drug: Modified treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified treatment including mirror confrontation
Study: 9865192
Drug: Combination CO2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination CO2 and PDL laser treatment
Study: 2136969
Drug: Anaritide (human
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anaritide (human atrial natriuretic peptide 102‐126) administered as 1‐hour infusions at a rate of 0.03 to 0.3 micrograms/kg/min
Study: 402543
Drug: Actihaemyl (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Actihaemyl (0.5 ml per kg body weight)
Study: 402543
Drug: Fludilat (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fludilat (200 mg)
Study: 402543
Drug: Trental (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trental (200 mg)
Study: 24102928
Drug: Gabapentin enacarbil
Normalized name: Gabapentin Enacarbil
DrugBank: Gabapentin enacarbil (DB08872)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gabapentin enacarbil (GEn) 3,600 mg/day
Study: 24102928
Drug: Gabapentin enacarbil
Normalized name: Gabapentin Enacarbil
DrugBank: Gabapentin enacarbil (DB08872)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gabapentin enacarbil (GEn) 1,200 mg/day
Study: 24102928
Drug: Gabapentin enacarbil
Normalized name: Gabapentin Enacarbil
DrugBank: Gabapentin enacarbil (DB08872)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gabapentin enacarbil (GEn) 2,400 mg/day
Study: 21576533
Drug: 100 mcg/d
Normalized name: Natpara 100 MCG/Dose Cartridge, 14 Dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mcg/d selenium supplementation
Study: 21576533
Drug: 200 mcg/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mcg/d selenium supplementation
Study: 21576533
Drug: 300 mcg/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mcg/d selenium supplementation
Study: 21576533
Drug: Selenium supplementation
Normalized name: Selenium supplements
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selenium supplementation (all doses)
Study: 14966737
Drug: Melatonin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melatonin (10 mg/kg) administered for 72 hours, starting within 3 hours after surgery.
Study: 9455079
Drug: Thiopental (TPS)
DrugBank: Thiopental (DB00599)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Thiopental (TPS) 4 mg.kg‐1
Study: 3285835
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg torasemide
Study: 3285837
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg torasemide
Study: 3285834
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg furosemide
Study: 3285834
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg furosemide
Study: 25560051
Drug: Terbinafine (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terbinafine (250 mg once daily)
Study: 25560051
Drug: Itraconazole (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Itraconazole (200 mg once daily)
Study: 18520293
Drug: Sunitinib at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sunitinib at 50 mg daily for 4 of 6 weeks
Study: 18520293
Drug: Sunitinib at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sunitinib at 37.5 mg daily (continuous dosing schedule)
Study: 15496230
Drug: Serum insulin-like
Normalized name: insulin-like growth factor 2
DrugBank: Insulin-like growth factor II (DB14472)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serum insulin-like growth factor-1 levels in systemic lupus erythematosus patients
Study: 15496230
Drug: Serum growth
Normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serum growth hormone levels in systemic lupus erythematosus patients
Study: 31714895
Drug: L-Citrulline 15
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-Citrulline 15 g/d for 2 weeks
Study: 22492584
Drug: Isomaltulose (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isomaltulose (50 g/day for 12 weeks)
Study: 22492584
Drug: Sucrose (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sucrose (50 g/day for 12 weeks)
Study: 16236879
Drug: Single 2.0-g
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single 2.0-g dose of azithromycin microspheres
Study: 16236879
Drug: Extended-release clarithromycin
Normalized name: clarithromycin Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended-release clarithromycin (1.0 g/d for 7 days)
Study: 8198976
Drug: levamisole 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: levamisole 2.5 mg kg‐1 day‐1 given for 2 days every week for 18 months
Study: 8198976
Drug: placebo therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo therapy in the same schedule
Study: 27387759
Drug: 3 months
Normalized name: TABLET, DOSE PACK, 3 MONTHS
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 months of oral antibiotics
Study: 27387759
Drug: No further
Approvals — FDA: no, EMA: no, PMDA: no
Description: No further antibiotic treatment (control)
Study: 19196360
Drug: Amlodipine/valsartan 5/160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine/valsartan 5/160 mg
Study: 24976417
Drug: Purported weight
Approvals — FDA: no, EMA: no, PMDA: no
Description: Purported weight loss supplement (placebo)
Study: 22551105
Drug: Warfarin (target
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin (target INR 2.0 to 3.5)